Table 1 Characteristics of patients with RA and healthy controls

Age, years

57.9 ± 8.7

58.3 ± 8.8

Female, n (%)

69 (85.2)

69 (85.2)

 Post-menopausal, n (%)

52 (75.4)

51 (73.9)

Height, cm

160.5 ± 7.0

160.8 ± 7.1

Weight, kg

62.5 ± 10.9

60.1 ± 10.7

BMI, kg/m²

24.2 ± 3.5

23.2 ± 3.4

Ever smoker, n (%)

17 (21.0)

–

Alcohol use, n (%)

18 (22.2)

–

Parental hip fracture, n (%)

9/77 (11.7)

–

Fall in the past year, n (%)

18/78 (23.1)

–

Duration of RA, years

5.7 (1.4–11.2)

–

RF or ACPA+, n (%)

74 (91.4)

–

 ACPA+, n (%)^a

53 (84.1)

–

DAS28-ESR

3.4 ± 1.5

–

DAS28-CRP

2.9 ± 1.4

–

SDAI

8.2 (3.2–16.2)

–

CDAI

7.0 (3.0–15.8)

–

HAQ-DI

0.05 (0.00–0.28)

–

GC ever, n (%)

55 (67.9)

–

 Current dose, mg/day

5.6 (5.0–10.0)

–

 Maximum dose, mg/day

10.0 (10.0–21.2)

–

 Duration, m

17.0 (6.5–58.0)

–

csDMARDs, n (%)

74 (91.4)

–

MTX ever, n (%)

57 (70.4)

–

LEF ever, n (%)

31 (38.3)

–

Sulfasalazine ever, n (%)

4 (4.9)

–

HCQ ever, n (%)

20 (24.7)

–

TWH ever, n(%)

29 (35.8)

–

bDMARDs ever, n (%)

14 (17.3)

–

Bisphosphonates, n (%)

7 (8.6)

0(0)